Compare Stocks

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HBPCF Helix BioPharma	$0.14	$0.14	$0.14 ▼ $0.15	$31.59M	-0.1	14 shs	N/A
KZIA Kazia Therapeutics	$0.39 -2.5%	$0.30	$0.19 ▼ $1.43	$6.36M	2.12	741,414 shs	103,928 shs
MACK Merrimack Pharmaceuticals	$14.71 -0.1%	$14.71	$11.53 ▼ $15.89	$213.74M	1.43	111,144 shs	106,490 shs
PVOTF BetterLife Pharma		$0.13	$0.03 ▼ $0.38	$21.70M	N/A	52,703 shs	198,200 shs
VRNA Verona Pharma	$15.24 -2.2%	$16.40	$11.83 ▼ $23.81	$1.26B	0.4	406,269 shs	244,005 shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HBPCF Helix BioPharma	0.00%	0.00%	-6.96%	-5.03%	-5.81%
KZIA Kazia Therapeutics	-1.52%	+13.38%	+45.15%	+5.28%	-70.66%
MACK Merrimack Pharmaceuticals	-0.14%	+0.20%	-0.14%	+10.60%	+21.57%
PVOTF BetterLife Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
VRNA Verona Pharma	-2.25%	-7.07%	-2.99%	-14.77%	-32.54%

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	0.6898 of 5 stars	3.5	0.0	0.0	0.0	0.0	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A
VRNA Verona Pharma	3.00	Buy	$33.60	120.47% Upside

Current Analyst Ratings

Latest MACK, PVOTF, VRNA, KZIA, and HBPCF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2024	VRNA Verona Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$31.00 ➝ $36.00
3/4/2024	VRNA Verona Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
3/1/2024	VRNA Verona Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$33.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	$20K	317.81	N/A	N/A	$0.50 per share	0.78
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	$0.01 per share	N/A
VRNA Verona Pharma	$460K	2,677.60	N/A	N/A	$3.10 per share	4.92

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HBPCF Helix BioPharma	-$4.69M	-$0.04	N/A	∞	N/A	N/A	-817.64%	-308.71%	6/12/2024 (Estimated)
KZIA Kazia Therapeutics	-$13.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	-$1.18M	-$0.08	N/A	∞	N/A	N/A	-6.24%	-6.09%	5/2/2024 (Estimated)
PVOTF BetterLife Pharma	-$14.78M	N/A	N/A	N/A	N/A	N/A	-205.15%	-147.23%	N/A
VRNA Verona Pharma	-$54.37M	-$0.69	N/A	N/A	N/A	N/A	-20.47%	-17.72%	5/14/2024 (Estimated)

Latest MACK, PVOTF, VRNA, KZIA, and HBPCF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	MACK Merrimack Pharmaceuticals	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A
2/29/2024	Q4 2023	VRNA Verona Pharma	-$0.23	-$0.16	+$0.07	-$0.16	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HBPCF Helix BioPharma	N/A	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HBPCF Helix BioPharma	N/A	1.46	1.46
KZIA Kazia Therapeutics	N/A	0.71	N/A
MACK Merrimack Pharmaceuticals	N/A	43.50	43.50
PVOTF BetterLife Pharma	N/A	3.62	3.62
VRNA Verona Pharma	0.20	33.33	33.33

Ownership

Institutional Ownership

Company	Institutional Ownership
HBPCF Helix BioPharma	N/A
KZIA Kazia Therapeutics	30.89%
MACK Merrimack Pharmaceuticals	63.97%
PVOTF BetterLife Pharma	N/A
VRNA Verona Pharma	85.88%

Insider Ownership

Company	Insider Ownership
HBPCF Helix BioPharma	7.60%
KZIA Kazia Therapeutics	1.00%
MACK Merrimack Pharmaceuticals	30.57%
PVOTF BetterLife Pharma	34.77%
VRNA Verona Pharma	4.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
HBPCF Helix BioPharma	9	229.44 million	212.00 million	Not Optionable
KZIA Kazia Therapeutics	2,021	16.34 million	16.18 million	Optionable
MACK Merrimack Pharmaceuticals	426	14.53 million	10.09 million	Optionable
PVOTF BetterLife Pharma	N/A	171.41 million	N/A	Not Optionable
VRNA Verona Pharma	79	80.82 million	76.94 million	Optionable

MACK, PVOTF, VRNA, KZIA, and HBPCF Headlines

Source	Headline
	Verona Pharma shares target raised on COPD launch outlook investing.com - April 25 at 3:40 AM
	Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update globenewswire.com - April 25 at 2:00 AM
	Verona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper Sandler americanbankingnews.com - April 17 at 3:36 AM
	Verona Pharma (NASDAQ:VRNA) Trading 3.7% Higher After Analyst Upgrade americanbankingnews.com - April 17 at 1:08 AM
	Verona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrade marketbeat.com - April 16 at 10:36 AM
	Verona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandler marketbeat.com - April 16 at 8:33 AM
	Verona Pharma (NASDAQ:VRNA) Shares Up 4.9% marketbeat.com - April 4 at 3:08 PM
	American Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA) marketbeat.com - March 28 at 4:07 AM
	VRNA Apr 2024 17.500 call finance.yahoo.com - March 16 at 8:32 AM
	VRNA Apr 2024 15.000 call finance.yahoo.com - March 16 at 3:31 AM
	Andrew Fisher Joins Verona Pharma as General Counsel globenewswire.com - March 4 at 2:00 AM
	Buy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipeline markets.businessinsider.com - March 1 at 1:10 PM
	Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 1 at 1:10 PM
	3 Healthcare Stocks That Have Outperformed Nvidia Since 2022 fool.com - March 1 at 8:45 AM
	Verona Pharma plc 2023 Q4 - Results - Earnings Call Presentation seekingalpha.com - February 29 at 11:18 AM
	Verona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update finanznachrichten.de - February 29 at 10:48 AM
	Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results finance.yahoo.com - February 29 at 10:48 AM
	Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update globenewswire.com - February 29 at 2:00 AM
	Verona Pharma earnings preview: what to expect markets.businessinsider.com - February 28 at 1:35 PM
	When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit? finance.yahoo.com - February 25 at 12:52 PM
	Verona Pharma PLC ADR wsj.com - February 25 at 7:52 AM
	VRNA Mar 2024 15.000 put finance.yahoo.com - February 17 at 7:46 PM
	VRNA Jun 2024 30.000 call finance.yahoo.com - February 17 at 2:46 PM
	Verona Pharma: A Few Points From The Bull And Bear Case seekingalpha.com - February 15 at 5:55 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Helix BioPharma

OTCMKTS:HBPCF

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Kazia Therapeutics

NASDAQ:KZIA

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

Merrimack Pharmaceuticals

NASDAQ:MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

BetterLife Pharma

OTCMKTS:PVOTF

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

Verona Pharma

NASDAQ:VRNA

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial